肺大细胞神经内分泌癌的治疗进展  

Advances of Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma

作　　者：孙佳怡 景亚婉 田攀文[1,3] 李为民[1] 李亚伦[1,3] Jiayi SUN;Yawan JING;Panwen TIAN;Weimin LI;Yalun LI(Department of Pulmonary and Critical Care Medicine,State Key Laboratory of Respiratory Health and Multimorbidity,Institute of Respiratory Health and Multimorbidity,Institute of Respiratory Health,Frontiers Science Center for Disease-related Molecular Network,Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Gerontology and Geriatrics,Tibet Autonomous Region People's Hospital,Lhasa 850000,China;Lung Cancer Center/Lung Cancer Institute,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院呼吸与危重症医学科,呼吸和共病全国重点实验室,呼吸健康研究所,疾病分子网络前沿科学中心,精准医学中心/精准医学四川省重点实验室,成都610041 [2]西藏自治区人民医院老年病科,拉萨850000 [3]四川大学华西医院肺癌中心,成都610041

出　　处：《中国肺癌杂志》2024年第8期622-628,共7页Chinese Journal of Lung Cancer

基　　金：国家自然科学基金项目(No.82072598,No.92159302);四川省科技项目(No.2022ZDZX0018)资助。

摘　　要：肺大细胞神经内分泌癌(large cell neuroendocrine carcinoma,LCNEC)是一种罕见且高度侵袭性的高级别神经内分泌癌,患者确诊时分期偏晚,预后差,其治疗策略多借鉴小细胞肺癌和非小细胞肺癌的方案。近年来,二代测序技术为LCNEC的精准分型提供了理论基础,研究也证实了不同LCNEC亚型与化疗方案疗效之间的关联性。免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)的应用,为LCNEC患者提供了新的治疗选择,但相关数据仅见于小样本的回顾性研究和少量个案报道。本文回顾了LCNEC的流行病学特征和经典治疗策略,并针对LCNEC的分子亚型研究进展和ICIs的应用进展进行综述,为临床治疗提供新思路。Large cell neuroendocrine carcinoma(LCNEC)of lung is a rare neuroendocrine carcinoma subtype with difficulty in early diagnosis and poor prognosis which is treated with standard strategies of small cell lung cancer and nonsmall cell lung cancer.In recent years,the precise types of LCNEC and its response to therapy have been identified by nextgeneration sequencing.Some researches have also found the correlation between different subtypes of LCNEC and the efficacy of chemotherapy regimens.However,there is no consensual agreement of its therapy.Recently,immune checkpoint inhibitors(ICIs)has provided a new option for LCNEC patients based on some retrospective research data and case reports.In this review,we aimed to summarize the epidemiological characteristics,standard therapy,the advances of molecular subtypes and clinical applications of ICIs of LCNEC,so as to provide optimal systemic clinical decision-making for LCNEC patients.

关 键 词：肺大细胞神经内分泌癌 分子分型 免疫检查点抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]